These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 10072624)
1. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Bruwer G; Heyns CF; Allen FJ Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624 [TBL] [Abstract][Full Text] [Related]
2. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240 [TBL] [Abstract][Full Text] [Related]
3. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer. Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119 [TBL] [Abstract][Full Text] [Related]
4. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer. Huncharek M; Muscat J Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590 [TBL] [Abstract][Full Text] [Related]
5. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680 [TBL] [Abstract][Full Text] [Related]
6. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Briganti A; Passoni N; Ferrari M; Capitanio U; Suardi N; Gallina A; Da Pozzo LF; Picchio M; Di Girolamo V; Salonia A; Gianolli L; Messa C; Rigatti P; Montorsi F Eur Urol; 2010 Apr; 57(4):551-8. PubMed ID: 20034730 [TBL] [Abstract][Full Text] [Related]
7. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Lee CT; Oesterling JE Urol Clin North Am; 1997 May; 24(2):389-94. PubMed ID: 9126236 [TBL] [Abstract][Full Text] [Related]
8. Is bone scintigraphy necessary in initial staging of prostate cancer patients? Jaukovic L; Adjinovic B; Cerovic S; Joksimovic M; Soldatovic Z Hell J Nucl Med; 2011; 14(2):126-30. PubMed ID: 21761013 [TBL] [Abstract][Full Text] [Related]
9. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up. Freitas JE; Gilvydas R; Ferry JD; Gonzalez JA J Nucl Med; 1991 Jul; 32(7):1387-90. PubMed ID: 1712383 [TBL] [Abstract][Full Text] [Related]
10. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Vijayakumar V; Vijayakumar S; Quadri SF; Blend MJ Am J Clin Oncol; 1994 Oct; 17(5):432-6. PubMed ID: 7522394 [TBL] [Abstract][Full Text] [Related]
11. When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer? Pal RP; Thiruudaian T; Khan MA Asian J Androl; 2008 Nov; 10(6):890-5. PubMed ID: 18958353 [TBL] [Abstract][Full Text] [Related]
12. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Gleave ME; Coupland D; Drachenberg D; Cohen L; Kwong S; Goldenberg SL; Sullivan LD Urology; 1996 May; 47(5):708-12. PubMed ID: 8650870 [TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Miller PD; Eardley I; Kirby RS Br J Urol; 1992 Sep; 70(3):295-8. PubMed ID: 1384920 [TBL] [Abstract][Full Text] [Related]
14. Role of serum prostate-specific antigen as predictor for bone metastases in newly diagnosed prostate cancer. Singh OP; Yogi V; Redhu P; Ghori HU; Pareek A; Lal N J Cancer Res Ther; 2019 Mar; 15(Supplement):S39-S41. PubMed ID: 30900618 [TBL] [Abstract][Full Text] [Related]
15. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen. Morote J; Lorente JA; Encabo G Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009 [TBL] [Abstract][Full Text] [Related]
16. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Haukaas S; Roervik J; Halvorsen OJ; Foelling M Br J Urol; 1997 May; 79(5):770-6. PubMed ID: 9158517 [TBL] [Abstract][Full Text] [Related]
17. The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer. Ataus S; Citçi A; Alici B; Onder AU; Sönmezoğlu K; Erözenci A; Solok V Int Urol Nephrol; 1999; 31(4):481-9. PubMed ID: 10668943 [TBL] [Abstract][Full Text] [Related]
18. A reappraisal of serial isotope bone scans in prostate cancer. O'Donoghue JM; Rogers E; Grimes H; McCarthy P; Corcoran M; Bredin H; Given HF Br J Radiol; 1993 Aug; 66(788):672-6. PubMed ID: 7536607 [TBL] [Abstract][Full Text] [Related]
19. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer]. Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388 [TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Wolff JM; Bares R; Jung PK; Buell U; Jakse G Urol Int; 1996; 56(3):169-73. PubMed ID: 8860738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]